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Randomised comparison of oral ofloxacin alone
with combination of parenteral antibiotics in
neutropenic febrile patients
Prompt treatment with empirical antibiotics in
neutropenic febrile patients reduces morbidity and
mortality. Most patients have been treated with
parenteral combination antibiotics, but newer
antibiotics with broad-spectrum bactericidal
activity have made monotherapy feasible.
Ofloxacin, a broad-spectrum fluoroquinolone, has
the additional advantage that bactericidal
concentrations can be achieved with oral
administration. We have compared ofloxacin as an
oral single agent with standard parenteral
combination antibiotics for the management of
neutropenic febrile patients in a prospective,
randomised trial.
Patients with severe neutropenia (absolute
neutrophil count &le;0&middot;5 &times; 109/l), fever above 38&deg;C,
and ability to take drugs by mouth were eligible for
the study. After initial investigations, 60 patients
were randomly assigned to oral ofloxacin 400 mg
twice daily and 62 to parenteral combination
antibiotic therapy (amikacin 15 mg/kg daily, plus, at
various times in the trial, carbenicillin, cloxacillin, or
piperacillin). Patients were examined 72 h and 7
days after the start of treatment and when
neutropenia resolved. 24 (40%) ofloxacin-treated
and 26 (42%) combination-treated patients had
pyrexia of unknown origin (PUO). In both
treatment groups, the treatment success rate was
higher for such patients than for those with
clinically or microbiologically documented
infections (92% vs 67% [p<0&middot;05] for ofloxacin;
85% vs 64% for combination). There were no
significant differences in success rates of ofloxacin
and combination treatment for these subgroups or
overall (77% vs 73%). Patients with neutropenia for
less than 1 week had better responses to both
treatments than patients with longer-lasting
neutropenia. There were 4 (7%) deaths in the
ofloxacin group and 6 (10%) in the combination
group. Both regimens were well tolerated.
We conclude that oral single-agent ofloxacin is as
effective as parenteral combination antibiotic
therapy in neutropenic febrile patients, especially
those expected to have short durations of
neutropenia.
Lancet 1992; 339: 1092-96.
Introduction
The prompt initiation of empirical broad-spectrum
antibiotic treatment in neutropenic febrile patients
significantly reduces morbidity and mortality.l,2 Owing to
the limited antibacterial spectra of older antibiotics, which
individually have an overall response rate of about 50%,
parenteral combination chemotherapy has been considered
necessary to achieve the synergy and high bactericidal
activity in serum that leads to a good outcome.3-5
Combination therapy also prevents the emergence of
resistant organisms.6 Such treatment is, however, expensive
and can be toxic, especially if aminoglycosides are part of the
combination.
Some newer antibiotics have a broad spectrum and
similar bactericidal activity to combination therapy7,8 and
have been used as single agents in the management of
neutropenic febrile patients. The newer fluoroquinolones
are potential agents for monotherapy. High bactericidal
serum concentrations can be achieved even when they are
given by mouth,9 which gives these drugs an enormous
advantage over parenteral antibiotics for cancer patients
with problems of venous access.
We have compared the quinolone ofloxacin given by
mouth with parenteral combination antibiotic therapy in a
randomised prospective study of neutropenic febrile
patients. The study was designed for haemodynamically
stable patients who were able to take drugs by mouth and
were expected to have short durations of neutropenia.
Patients and methods
All patients treated by the oncology service during the 2 years
1989-91 entered the study if they had fever above 38&deg;C measured
orally at least twice 4 h apart in a day, or a single value of38-5&deg;C or
higher unrelated to the administration of pyrogenic agents; and an
absolute neutrophil count of 0-5 x 109/1 or lower, or a count below
1 ’0 x 109/1 as long as it fell below 0-5 x 109/1 within 24 h of entry to
the study. Reasons for exclusion were: known hypersensitivity to
any of the antibiotics used or related products; antibiotic treatment
within the preceding 96 h; pregnancy; lactation; age under 16 years;
renal insufficiency (serum creatinine >221 umol/1 or need for
dialysis); hepatic insufficiency (alanine aminotransferase activity
more than 4 times normal); inability to take oral medications caused
by painful mouth ulcers, intestinal malabsorption, or severe nausea
and vomiting; recurrent pyrexia of undetermined origin (PUO);
and shock (systolic blood pressure < 80 mm Hg or peripheral
circulatory failure).
After giving informed consent, each patient underwent a
complete physical examination with history-taking, complete blood
count, urine analysis, measurement of blood urea nitrogen,
creatinine, and electrolytes, liver function tests, and chest
radiography. Cultures of throat swabs, urine, and faeces, at least two
blood cultures, and fme-needle aspiration and culture of any
possible source of infection were done. The sensitivities of microbial
isolates were assessed on Kirby-Bauer agar-diffusion plates.
Patients were then randomly assigned one of the treatment
regimens by means of consecutively drawn sealed envelopes.
Patients assigned ofloxacin received 400 mg/kg daily. Patients
assigned parenteral treatment received one of three combinations.
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TABLE I-CLINICAL CHARACTERISTICS OF STUDY PATIENTS
We chose amikacin (15 mg/kg daily) because gentamicin resistance
among gram-negative isolates at our hospital is conunon.10 Initially,
we combined amikacin with carbenicillin (400 mg/kg daily) but the
high cost of this drug in such doses and the high rate of carbenicillin
resistance in pseudomonas isolateslO led us to discontinue its use.
Owing to the prominence of gram-positive isolates we changed to
cloxacillin (1 g every 6 h). We later changed to piperacillin (4 g every
4 h) when this drug became available in our hospital, to provide
better activity against gram-negative organisms and so that we were
comparing ofloxacin with the best available combination.
Each febrile episode was classified as either due to a clinically or
microbiologically documented infection or of undetermined origin
(PUO). For a microbiologically documented infection, bacterial
pathogens were isolated from blood, bone marrow, urine, pus, or
exudates and there was clinical, laboratory, or radiographic
evidence of infection at the same sites. Criteria for microbiologically
documented infection were similar to those of Pizzo et al. 11 In a
clinical infection, there was clear clinical evidence of infection but no
organism could be isolated. This category included cellulitis,
culture-negative pneumonia, necrotising oral mucositis, and
marginal gingivitis. PUO was defmed as an episode for which there
was no clinical or microbiological evidence of infection within 72 h
of entry to the study.
Clinical and microbiological outcome were evaluated at 72-96 h,
7 days after the start of antibiotic treatment, and at the resolution of
neutropenia, so that we could assess the efficacy of treatment. 12 Each
patient was physically examined every day. Blood cultures and
counts were done daily if fever persisted at 38&deg;C or above. Liver
function tests, clotting profile, and chest radiography were repeated
weekly if fever persisted. Treatment outcomes were classified into
three categories .12
Failure--Patients whose infections progressed within 72 h,
shown by the presence of worsening obvious source of infection,
shock, or continuing positive blood cultures, were considered to
have treatment failure and were withdrawn from the study.
Persistence of fever alone was considered a treatment failure if there
was no change after 4 days of antibiotic therapy, unless an identified
site of infection had shown substantial improvement. This category
also included patients who initially responded to treatment but
ultimately did not recover from fever and neutropenia and died.
Success without modification-- These patients recovered from
fever and neutropenia without any modification of the initial
regimen.
Success with modification-included eposides in which the
patient recovered from the fever and neutropenia but required
additional treatment with an antibiotic against gram-positive or
gram-negative organisms as well as empirical antifungal treatment
with amphotericin or antiviral therapy with acyclovir. However,
crossover from one arm to the other was not permitted.
Nephrotoxicity was defined as a rise of 44 umol/1 in serum
creatinine from the previous measurement. Hepatotoxicity was
defined as a doubling of pretreatment activities of aminotransferases
or alkaline phosphatase. Other toxic effects (eg, drug-related rashes)
TABLE II-BACTERIAL ISOLATES FROM PATIENTS WITH PROVEN
INFECTIONS
*Two isolates were obtained for 4 patients Numbers represent initial isolates with
breakthrough isolates in parentheses-
were individually determined. Amikacin concentrations were not
routinely measured. Antibiotic dose was adjusted for renal
impairment.
The Epi Info statistical package was used for the preliminary
analysis. Initially all 137 subjects (68 ofloxacin, 69 combination)
were included in an analysis of clinical characteristics. 15
randomised patients (8 ofloxacin, 7 combination) were excluded
because the neutrophil count did not fall below 0-5 x 109/1 within
24 h (in 10 patients), the patient had received antibiotics within the
previous 96 h (3), a rash developed (1 ofloxacin-treated patient), or
because the patient was in shock at entry (1). These 15 patients did
not differ significantly from the 122 evaluable patients in any clinical
characteristic apart from mean neutrophil count and duration of
TABLE III-RESPONSE RATES AND SURVIVAL DATA
*Significantly higher than ofloxacin for documented infections (p<0 05)
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Fig 1-Effect of duration on clinical response.
neutropenia (the main reason for patient exclusion was lack of
expected fall in the neutrophil count). More of the excluded patients
had PUO than had documented infections. However, exclusion of
these patients had no significant effect on any study variable.
Subsequent reanalysis was done for 122 patients. The three
combination groups were analysed separately but did not differ
significantly in response rate so for all purposes were analysed
collectively as the combination arm.
Response rates in the two groups were compared by Fisher’s
exact test (causes of fever and response rate in relation to type of
success) or the chi-square test (all other comparisons). Duration of
fever was used to calculate Kaplan-Meier survival curves and
differences between the curves were estimated by log-rank analysis.
Results
No episode of renal or hepatic toxicity occurred during
the study in any of the 137 patients initially entered. 15
randomised patients were excluded (see methods); of the
remaining 122 patients, 60 were treated with ofloxacin and
62 with parenteral combination therapy (10
amikacin + carbenicillin, 41 amikacin + cloxacillin, 11 
amikacin + piperacillin). The ofloxacin and combination
groups were well matched for age, sex, underlying
neoplasm, mean neutrophil count, and duration of
neutropenia (table I).
At the initial evaluation (at 72 h) 50 patients had PUO, 32
had clinically documented infection, 25 microbiologically
documented infection without bacteraemia, and 15 (12%)
documented bacteraemia (table I). The most striking feature
Fig 2-Time to treatment failure.
of the organisms isolated (table II) is the frequency of
gram-positive isolates from blood cultures.
There were no significant differences between the
ofloxacin and combination groups in clinical success rate,
though within each treatment group the success rate was
higher for patients with PUO than for those with clinically
or microbiologically documented infections; the difference
reached significance in the ofloxacin group (p < 0’05; table
III). Bacteraemia recurred in 5 patients in the combination
group and 2 in the ofloxacin group. These cases were
considered treatment failures. The average duration of fever
was similar in both groups. The difference in death rate
between the combination and ofloxacin groups was not
significant, though our sample size may be too small to
detect a difference. 1 ofloxacin-treated patient died on day 4
and 1 patient receiving the antibiotic combination died on
day 6. All 8 other deaths occurred after 2 weeks in patients
who were receiving multiple antibiotics and antifungal
treatment. The duration of neutropenia contributed
substantially to the success rate in both groups. Among both
ofloxacin-treated and combination-treated patients, those
who had neutropenia for less than a week had significantly
higher success rates than those with longer-lasting
neutropenia (p<0-05 and < 0-001, respectively; fig 1).
There was no significant difference between the groups in
time to treatment failure (fig 2).
Discussion
Despite substantial improvements in the supportive care
of patients with malignant disorders, the clinical course of
patients with neutropenia continues to be complicated by
fever and infection. 13 60 % of such febrile episodes are due to
microbiologically or clinically documented infection.14 The
pathogens that cause the initial infections are few (table II).
Although gram-positive organisms are being isolated with
increasing frequency, gram-negative pathogens contribute
50% of isolates in most studies and account for early
morbidity and mortality.1s The standard approach to
treatment has been to use a parenteral antibiotic
combination, especially for the management of the more
virulent gram-negative infections.5-7 However, the potential
toxic effects on kidney and ears of aminoglycosides, the risk
of antibiotic antagonism with double beta-lactam
combinations,16 and the high cost are drawbacks;
monotherapy has become feasible with the availability of
broad-spectrum bactericidal agents.
There have been several comparative trials of a broad-
spectrum single agent vs antibiotic combinations.2,17-24 The
fluoroquinolones are well tolerated, with fewer adverse
effects than more commonly used agents, they are
bactericidal against most species of bacteria, and their oral
bioavailability exceeds 50%.9 These features make the
fluoroquinolones almost ideal agents for monotherapy in
neutropenic febrile patients. Ease of administration of
ofloxacin by mouth to patients with compromised venous
access and the cost-effectiveness of monotherapy prompted
our comparative trial.
Our two study groups were similar as regards
demographic and clinical characteristics; most importantly,
similar proportions had PUO, and the rate of PUO was
lower than in a previous study" of ceftazidime vs
combination therapy in which the proportions with PUO
were 67% vs 76%, respectively. The high percentage of
patients in our study who had documented clinical or
microbiological infection makes the efficacy of ofloxacin
more impressive. Exclusion of patients in shock and those
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unable to take drugs by mouth could have biased the results
in favour of ofloxacin. We were unsure how well ofloxacin
would be absorbed in a patient with haemodynamic
compromise, so we excluded all patients in shock. Until the
use of ofloxacin in shock is tested in a controlled trial, we do
not recommend such use. Antibiotic concentrations were
not routinely measured in our study patients. Although such
measurements confirm the adequacy of the antibotic dose,
our overall success rate is similar to rates when
aminoglycoside concentrations were closely monitored.11
Our study may be criticised for the changes made in the
combination antibiotics group. The study was designed to
compare oral single agent with parenteral combination
antibiotics. The changes in combination therapy could not
have affected patient selection, but they could have altered the
efficacy of combination treatment. Comparison of the overall
success rate with each of the three combinations showed no
significant differences. Since the overall success rate and
mortality of our combination group are similar to or better
than those reported by others, we believe that changes in the
combination treatment did not adversely affect the results.
Ciprofloxacin has equal efficacy in combination with
aminoglycosides or with beta-lactam antibiotics.22,25,26
However, one study suggested that it was less effective in
gram-positive than in gram-negative bacteraemias. The
limited efficacy against streptococci can lead to
superinfection in neutropenic patients receiving
ciprofloxacin as sole therapy.23 In our study, only 1 patient
had breakthrough bacteraemia with Streptococcus viridans in
the ofloxacin group. Although this episode was classified as a
treatment failure, it did not cause death. However, 3 of 5
patients with breakthrough bacteraemia in the combination
group died.
Wide variations of study design and endpoints can lead to
conflicting results.27 Pizzo et all’ suggest ultimate patient
survival as the endpoint, whereas others emphasise the
importance of treatment of infection and development of
subsequent infections. The criteria for failure in our study,
similar to those of EORTC,28 meant that the death rate was
much lower than the failure rate. In addition, crossover was
not permitted. With death as the only criterion of failure,"
our overall success rates were even higher (93% with
ofloxacin and 90% with combination antibiotics). In our
study, as in the EORTC study,28 there was a significant
difference in outcome for PUO and for documented
infections in the monotherapy group;211 there was also a
difference between these two categories with combination
treatment, though it was not significant.
A significantly lower response rate has been reported for
patients who have profound neutropenia for a long time than
for patients with less severe or long-lasting neutropenia.3,4
The number of circulating granulocytes is the single most
important factor in determining efficacy of an antibiotic
regimen. In both our treatment groups, response rates were
lower in the patients with neutropenia for longer than a week.
A possible disadvantage of monotherapy is the greater
potential for development of resistance during treatment
than with a combination. Emergence of resistance has been
reported with the broad-spectrum penicillins 2429 but Pizzo
et al did not observe resistance during 5 years ofceftazidime
use.ll Resistance to ciprofloxacin despite concomitant
treatment with other antibiotics was reported in one study
but not in others.22,26,30 An outbreak of ciprofloxacin-
resistant Staphylococcus epidermidis was reported by Chan et
al.25 During 2 years’ use of ofloxacin, we did not see any cases
of resistance.
Our most important finding is that a single agent taken by
mouth was as effective as combination antibiotic therapy in
neutropenic febrile patients. Oral ofloxacin is cheap, well-
tolerated, non-toxic, and the most cost-effective way to
manage patients with fever and neutropenia. In Pakistan,
the combination therapy is thirteen times more expensive
than ofloxacin alone. In developing countries, cost is an
important factor that influences compliance and ultimate
care. Ofloxacin seems to be especially suitable for patients
who are expected to have short durations of neutropenia.
Use of ofloxacin might allow early discharge from hospital of
a patient who becomes afebrile but continues to be
neutropenic. It could even enable effective outpatient
management of such neutropenic febrile patients. A trial of
outpatient use of ofloxacin is underway.
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REVIEW ARTICLE
Salmonella-triggered reactive arthritis
Introduction
Salmonella infections are becoming more common
around the world. 1 Sometimes the consequences of
salmonella infection may be more serious than a brief
episode of gastroenteritis, since reactive arthritis (ReA) may
follow infection.2-5 The incidence of ReA after salmonella
infection has been reported to be between 1-2 and 7-3% 2
and an increase in the number of salmonella ReA cases has
been noted.3 Clinical manifestations of ReA vary from slight
arthralgia to severe disabling disease. ReA often appears one
to three weeks after the onset of gastrointestinal infection
and presents as a migratory, asymmetrical polyarthropathy.
The pathogenesis of ReA remains unknown. We now
review the latest findings with regard to salmonella-
triggered ReA.
Aetiology
Of the 2000 different salmonella serotypes, 22 have been
reported to trigger ReA.2 About 60% of ReA cases are
triggered by Salmonella typhimurium and 25% by
S enteritidis, and over 90% of cases are triggered by
salmonellae that have O-antigens in common with these two
species (serotypes B and D). We have described ReA after
infections with S montevideo, Sagona, S saint paul, and S
java, species not previously reported to induce ReA.4,s It has
also been reported that the organisms need not be viable,
since ReA has been observed after vaccination with
heat-killed whole S typhi in two patients.6
Diagnosis
Diagnosis is based on both clinical fmdings and
laboratory evidence of salmonella infection. A defmite
diagnosis of salmonella infection can be made only by
isolation of organisms from the patient. However, by the
time arthritic complications appear, the patient has usually
recovered from gastroenteritis and salmonella may no longer
be detectable in faeces. Consequently, laboratory diagnosis
of salmonella-triggered ReA often depends on detection of
specific antibodies.2 The Widal agglutination test, first
described in 1896, is the earliest and still most widely used
serological test for salmonella infections; however, its value
has been questioned.2 Tests for specific salmonella serotypes
are laborious because of the large variety of serotypes
and antigens. We have overcome this difficulty with an
enzyme immunoassay (EIA) that detects antibodies to the
lipopolysaccharides (LPSs) of S typhimurium and
S enteritidis. At least 70% of the salmonellae isolated from
humans, and more than 90% of those causing ReA, have
0 side chains on their LPS that are identical to those of
S typhimurium and S enteritidis.2 Moreover, the structure of
the lipid A core of LPS is conserved among different species
of salmonella, thus broadening the test’s applicability. The
EIA is more sensitive than the Widal test, and its value in
clinical diagnosis of salmonella-triggered ReA has been
demonstrated .4.511-10
In addition to serological tests, salmonella infections can
be diagnosed by detecting salmonella antigens in joints
or peripheral blood cells by immunofluorescence or
immunoblotting,9 or by measuring the proliferative
responses of synovial fluid or peripheral blood mononuclear
cells to salmonella organisms." However, these tests are too
laborious for routine diagnosis.
Pathogenesis
Several theories have been advanced to explain how
inflammation in joints may be stimulated by microbial
antigens originating from a remote site in the body. All these
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